These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 24755473)

  • 1. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
    Grassian AR; Parker SJ; Davidson SM; Divakaruni AS; Green CR; Zhang X; Slocum KL; Pu M; Lin F; Vickers C; Joud-Caldwell C; Chung F; Yin H; Handly ED; Straub C; Growney JD; Vander Heiden MG; Murphy AN; Pagliarini R; Metallo CM
    Cancer Res; 2014 Jun; 74(12):3317-31. PubMed ID: 24755473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductive carboxylation supports redox homeostasis during anchorage-independent growth.
    Jiang L; Shestov AA; Swain P; Yang C; Parker SJ; Wang QA; Terada LS; Adams ND; McCabe MT; Pietrak B; Schmidt S; Metallo CM; Dranka BP; Schwartz B; DeBerardinis RJ
    Nature; 2016 Apr; 532(7598):255-8. PubMed ID: 27049945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
    Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
    Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
    Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
    J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
    Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
    Hollinshead KER; Munford H; Eales KL; Bardella C; Li C; Escribano-Gonzalez C; Thakker A; Nonnenmacher Y; Kluckova K; Jeeves M; Murren R; Cuozzo F; Ye D; Laurenti G; Zhu W; Hiller K; Hodson DJ; Hua W; Tomlinson IP; Ludwig C; Mao Y; Tennant DA
    Cell Rep; 2018 Mar; 22(12):3107-3114. PubMed ID: 29562167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
    Stuani L; Sabatier M; Saland E; Cognet G; Poupin N; Bosc C; Castelli FA; Gales L; Turtoi E; Montersino C; Farge T; Boet E; Broin N; Larrue C; Baran N; Cissé MY; Conti M; Loric S; Kaoma T; Hucteau A; Zavoriti A; Sahal A; Mouchel PL; Gotanègre M; Cassan C; Fernando L; Wang F; Hosseini M; Chu-Van E; Le Cam L; Carroll M; Selak MA; Vey N; Castellano R; Fenaille F; Turtoi A; Cazals G; Bories P; Gibon Y; Nicolay B; Ronseaux S; Marszalek JR; Takahashi K; DiNardo CD; Konopleva M; Pancaldi V; Collette Y; Bellvert F; Jourdan F; Linares LK; Récher C; Portais JC; Sarry JE
    J Exp Med; 2021 May; 218(5):. PubMed ID: 33760042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
    Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
    Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
    Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
    Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of IDH1 aggravates the fatty acid‑induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain.
    Li S; Sun C; Gu Y; Gao X; Zhao Y; Yuan Y; Zhang F; Hu P; Liang W; Cao K; Zhang J; Wang Z; Ye J
    Mol Med Rep; 2019 Apr; 19(4):2509-2518. PubMed ID: 30720071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
    Leonardi R; Subramanian C; Jackowski S; Rock CO
    J Biol Chem; 2012 Apr; 287(18):14615-20. PubMed ID: 22442146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
    Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
    Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
    MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
    Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
    Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
    Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
    Zhang GF; Jensen MV; Gray SM; El K; Wang Y; Lu D; Becker TC; Campbell JE; Newgard CB
    Cell Metab; 2021 Apr; 33(4):804-817.e5. PubMed ID: 33321098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.